Using analog insulin rather than human or animal-derived insulin [90] |
Having high baseline hypoglycemia or fear of hypoglycemia [64, 90–92] |
Using basal insulin rather than rapid- or short-acting insulin [2] |
Having high comorbidity burden [90] |
Being in age group (40–69) [90] |
Experiencing or having fear of weight gain [92, 93] |
Experiencing improved glycemic control [93] |
Experiencing or having fear of pain from injection [64, 93] |
Having access to support system formed primarily of physicians and healthcare professionals [93] |
Feeling financially burdened [64, 94] |
Using injection pen rather than vial or syringe [63] |
Having complex regimen [64] |
Having been treated for diabetes for longer duration [64] |
Starting with higher dose [64] |
Having higher baseline HbA1c level [90, 92] |
Feeling that insulin treatment interferes with daily activities [64] |